Trial · NCT06622603
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of patients with serum urate levels <7.0 mg/dL | 6 months | The proportion of patients who maintain serum urate levels \<7.0 mg/dL at 6 months after taking febuxostat 20 mg once daily or after suspending urate-lowering agents |
| Secondary | The proportion of subjects with serum urate <7.0 mg/dL | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Serum urate levels | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Gout Impact Scale (GIS) score using the Korean version | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Patient's overall assessment of gout using a visual analog scale | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | EuroQol(EQ)-5D score | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months |
| Secondary | Gout activity score (GAS) | 6 months and 12 months | GAS is calculated as (0.09 × last 12-month attacks) + \[1.01 × square root (serum uric acid)\] + \[0.34 × VAS patient\] + \[0.53 × ln (1 + tophi number)\] We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
| Secondary | Drug adherence | 6 months and 12 months | Adherence is defined as defined as taking 80% or more of the prescribed medication (using by the number of remaining pills). We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
| Secondary | Incidence rate of acute gouty arthritis | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
| Secondary | Swollen and tender joint counts of 66/68 joints | 6 months and 12 months | We will compare among maintaining, reducing, and discontinuing groups at 6 months and between maintaining and reducing groups at 12 months. |
| Other | The reliability of the ultrasound scoring system for tophi in gout patients | Baseline | We will compare the USG scores evaluated by each institution with ones evaluated by an independent review committee. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06622603/registered